Citius Oncology (CTOR) Return on Capital Employed (2023 - 2026)

Citius Oncology's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 93.55% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 4803.0% year-over-year to 93.55%; the TTM figure through Mar 2026 stood at 93.55% (down 4803.0% YoY), while the FY2025 annual figure was 54.5%, down 957.0% from the prior year.
• Return on Capital Employed was 93.55% for Q1 2026 at Citius Oncology, down from 36.84% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 9.21% in Q4 2023 to a low of 93.55% in Q1 2026.
• Historically, Return on Capital Employed has averaged 40.36% across 4 years, with a median of 36.84% in 2025.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 78 bps in 2025, then tumbled 4803 bps in 2026.
• A 4-year view of Return on Capital Employed shows it stood at 9.21% in 2023, then slumped by 292 bps to 36.06% in 2024, then retreated by 2 bps to 36.84% in 2025, then sank by 154 bps to 93.55% in 2026.
• The last three Return on Capital Employed figures came in at 93.55% (Q1 2026), 36.84% (Q4 2025), and 50.23% (Q3 2025), per Business Quant data.